SHELTON, Conn.--(BUSINESS WIRE)--Pitney Bowes today announced the launch of a new Temu integration within ShipAccel®, its cloud-based shipping and order management solution. The integration is ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Generate:Biomedicines has hit the public markets as the world begins to question the usefulness of AI technology. CEO Mike Nally says biology is the key to unlocking the technology’s full potential.

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

AI drug discovery specialist Generate Biomedicines has raised $400 million in the year’s largest initial public offering to date for a biotechnology firm. The company, which was launched in 2018 by ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

In industrial and engineering operations, maintaining accurate and professional identification is essential for safety, compliance, and asset management. However, traditional label creation often ...

The Gmail mobile apps lack a handful of features found on the website, but Google is now adding the ability to create new labels on Android. Once available, open the navigation drawer for “Create ...

After testing the feature since December, Google is finally rolling out “create and manage labels” to Gmail for Android. Previously exclusive to desktop and iOS, this update allows Android users to ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...